CRISPR/Cas13-mediated RNA Targeting Therapy for the Treatment of nAMD Investigator-Initiated Trial (SIGHT-I)
Condition: Neovascular Age-related Macular Degeneration(nAMD) Intervention: Genetic: HG202 Sponsors: HuidaGene Therapeutics Co., Ltd.; Tianjin Medical University Eye Hospital; Eye & ENT Hospital of Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials